EQL PHARMA AB Financial Flexibility Index
EQL PHARMA AB financial flexibility index. EQL PHARMA AB (7JK) has a Financial Flexibility Index of 0.06x as of March 2026. Free cash flow of €34.01 Million (operating CF €16.79 Million minus capex €17.22 Million) represents 0% of total liabilities (€583.83 Million). Explore 7JK capex to operating cash flow ratio to see what proportion of operating cash flow is directed to capital expenditures.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Financial Flexibility Index of EQL PHARMA AB (2022–2026)
Financial flexibility index of EQL PHARMA AB from 2022 to 2026. Historical Financial Flexibility Index trend for EQL PHARMA AB across 5 annual periods. Check 7JK capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
EQL PHARMA AB Financial Flexibility Index by Year (2022–2026)
EQL PHARMA AB financial flexibility index by year from 2022 to 2026. Year-by-year free cash flow to debt coverage for EQL PHARMA AB. For the full cash flow conversion analysis, see 7JK cash flow conversion.
| Year | Flexibility Index | Free Cash Flow (EUR) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2026 | 0.16x | €95.60 Million | €28.36 Million | €583.83 Million | ▼ -56.5% |
| 2025 | 0.38x | €221.19 Million | €-24.65 Million | €587.79 Million | ▲ +34.6% |
| 2024 | 0.28x | €54.83 Million | €-11.44 Million | €196.03 Million | ▼ -23.9% |
| 2023 | 0.37x | €48.12 Million | €27.62 Million | €130.94 Million | ▼ -34.3% |
| 2022 | 0.56x | €63.92 Million | €41.83 Million | €114.26 Million | — |